Want to see IL:INCR full AI Analyst Report?
INCR Stock Chart & Stats
1720.00
-2.90(-0.99%)
At close: 4:00 PM EDT
1720.00
-2.90(-0.99%)
Day’s Range― - ―
52-Week Range1,126.50 - 2,575.00
Previous CloseN/A
Volume119.26K
Average Volume (3M)4.90K
Market Cap
₪167.02M
Enterprise Value309.28M
Total Cash (Recent Filing)₪46.67M
Total Debt (Recent Filing)₪183.01M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
May 06, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding11,845,711
10 Day Avg. Volume6,212
30 Day Avg. Volume4,898
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe return to revenue growth indicates that InterCure regained commercial momentum after two weaker years. If maintained, expanding sales can improve operating leverage, support broader product distribution, and provide a stronger base for restoring profitability over the next several quarters.
Improved Cash GenerationPositive operating and free cash flow in 2025 shows a meaningful improvement in the company’s ability to fund operations internally. Sustained cash generation would reduce reliance on external financing, support product and channel investment, and strengthen financial resilience.
Manageable LeverageThe lower debt-to-equity ratio and relatively stable equity base indicate that leverage is currently manageable. This gives InterCure greater flexibility to navigate its operating recovery and fund ongoing activities without the balance sheet appearing excessively burdened.
Bears Say
Persistent Net LossesInterCure has not yet converted its revenue recovery into consistent profitability, with net losses continuing through 2025. Persistent losses can constrain reinvestment, weaken retained capital, and limit the durability of the recent financial improvement if growth does not accelerate.
Gross Margin CompressionSharp gross-margin compression signals weaker economics on the company’s sales than in earlier periods. Unless margins stabilize, additional revenue may translate into limited earnings improvement, making it harder for InterCure to achieve sustainable operating profitability.
Cash Flow VolatilityAlthough 2025 cash generation improved, the preceding two years of substantial outflows show that performance has been volatile. This history makes the latest improvement less established and could create recurring pressure on liquidity and investment capacity if outflows return.
Intercure News
INCR FAQ
What was InterCure’s price range in the past 12 months?
InterCure lowest stock price was 1126.50 and its highest was 2575.00 in the past 12 months.
What is InterCure’s market cap?
InterCure’s market cap is ₪167.02M.
When is InterCure’s upcoming earnings report date?
InterCure’s upcoming earnings report date is May 06, 2027 which is in 193 days.
How were InterCure’s earnings last quarter?
InterCure released its earnings results on Feb 19, 2026. The company reported -314.2 earnings per share for the quarter.
Is InterCure overvalued?
According to Wall Street analysts InterCure’s price is currently Overvalued.
Does InterCure pay dividends?
InterCure does not currently pay dividends.
What is InterCure’s EPS estimate?
InterCure’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InterCure have?
InterCure has 11,845,711 shares outstanding.
What happened to InterCure’s price movement after its last earnings report?
InterCure reported an EPS of -314.2 in its last earnings report. Following the earnings report the stock price went up 1.101%.
Which hedge fund is a major shareholder of InterCure?
Currently, no hedge funds are holding shares in IL:INCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InterCure
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to production, marketing, and distribution of medical cannabis products. The company's product line features dried cannabis flowers and an oil-based cannabis extract. Additionally, InterCure allocates investments to the biomedical sector. Established in 1994, the firm's main headquarters are situated in Herzliya, Israel.